Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that it will present clinical research findings of 9MW1911 in healthy subjects through poster presentations at the 2025 European Respiratory Society (ERS) Congress in Amsterdam, the Netherlands from September 27 to October 1, 2025. The ERS Annual Congress ranks among the world's premier academic conferences in respiratory medicine.

Poster Presentation

Abstract title：First-in-human study of 9MW1911 (an anti-ST2 monoclonal antibody) in healthy volunteers

Abstract Number: 51314

Poster Number: PA2475

Session Date and Time: Sept. 29, 2025, 7:30 AM-11:00 AM (local time)

About 9MW1911

9MW1911 is a novel anti-ST2 monoclonal antibody independently developed through Mabwell's proprietary B-lymphocyte screening platform. It demonstrates high affinity and potent bioactivity. Preclinical studies have revealed its well-characterized mechanism of action – by specifically binding to ST2, it effectively blocks IL-33-induced activation of ST2-mediated signaling pathways, suppressing inflammatory responses to potentially treat various autoimmune diseases. Currently, a Phase II clinical study of 9MW1911 for chronic obstructive pulmonary disease (COPD) is ongoing.